Item request has been placed!
×
Item request cannot be made.
×
![loading](/sites/all/modules/hf_eds/images/loading.gif)
Processing Request
On model-based time trend adjustments in platform trials with non-concurrent controls.
Item request has been placed!
×
Item request cannot be made.
×
![loading](/sites/all/modules/hf_eds/images/loading.gif)
Processing Request
- معلومة اضافية
- المصدر:
Publisher: BioMed Central Country of Publication: England NLM ID: 100968545 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2288 (Electronic) Linking ISSN: 14712288 NLM ISO Abbreviation: BMC Med Res Methodol Subsets: MEDLINE
- بيانات النشر:
Original Publication: London : BioMed Central, [2001-
- الموضوع:
- نبذة مختصرة :
Background: Platform trials can evaluate the efficacy of several experimental treatments compared to a control. The number of experimental treatments is not fixed, as arms may be added or removed as the trial progresses. Platform trials are more efficient than independent parallel group trials because of using shared control groups. However, for a treatment entering the trial at a later time point, the control group is divided into concurrent controls, consisting of patients randomised to control when that treatment arm is in the platform, and non-concurrent controls, patients randomised before. Using non-concurrent controls in addition to concurrent controls can improve the trial's efficiency by increasing power and reducing the required sample size, but can introduce bias due to time trends.
Methods: We focus on a platform trial with two treatment arms and a common control arm. Assuming that the second treatment arm is added at a later time, we assess the robustness of recently proposed model-based approaches to adjust for time trends when utilizing non-concurrent controls. In particular, we consider approaches where time trends are modeled either as linear in time or as a step function, with steps at time points where treatments enter or leave the platform trial. For trials with continuous or binary outcomes, we investigate the type 1 error rate and power of testing the efficacy of the newly added arm, as well as the bias and root mean squared error of treatment effect estimates under a range of scenarios. In addition to scenarios where time trends are equal across arms, we investigate settings with different time trends or time trends that are not additive in the scale of the model.
Results: A step function model, fitted on data from all treatment arms, gives increased power while controlling the type 1 error, as long as the time trends are equal for the different arms and additive on the model scale. This holds even if the shape of the time trend deviates from a step function when patients are allocated to arms by block randomisation. However, if time trends differ between arms or are not additive to treatment effects in the scale of the model, the type 1 error rate may be inflated.
Conclusions: The efficiency gained by using step function models to incorporate non-concurrent controls can outweigh potential risks of biases, especially in settings with small sample sizes. Such biases may arise if the model assumptions of equality and additivity of time trends are not satisfied. However, the specifics of the trial, scientific plausibility of different time trends, and robustness of results should be carefully considered.
(© 2022. The Author(s).)
- References:
J Biopharm Stat. 2012;22(4):758-72. (PMID: 22651113)
Clin Pharmacol Ther. 2021 Aug;110(2):311-320. (PMID: 33506495)
Drug Des Devel Ther. 2021 Sep 22;15:3997-4009. (PMID: 34588764)
Stat Probab Lett. 2011 Jul;81(7):767-772. (PMID: 21769160)
Mol Psychiatry. 2022 Mar;27(3):1286-1299. (PMID: 34907394)
Clin Pharmacol Ther. 2022 Dec;112(6):1183-1190. (PMID: 35253205)
Pharm Stat. 2014 Jan-Feb;13(1):41-54. (PMID: 23913901)
Trials. 2021 Mar 10;22(1):203. (PMID: 33691748)
Clin Gastroenterol Hepatol. 2022 Mar;20(3):e564-e572. (PMID: 34091047)
Clin Trials. 2022 Oct;19(5):490-501. (PMID: 35993547)
Clin Pharmacol Ther. 2020 Apr;107(4):806-816. (PMID: 31725899)
Control Clin Trials. 1988 Dec;9(4):327-44. (PMID: 3203524)
Biometrics. 2014 Dec;70(4):1023-32. (PMID: 25355546)
Orphanet J Rare Dis. 2020 Mar 12;15(1):69. (PMID: 32164754)
Clin Ther. 2020 Jul;42(7):1330-1360. (PMID: 32622783)
Pharm Stat. 2021 Nov;20(6):1002-1016. (PMID: 33908160)
Nat Rev Dis Primers. 2016 Sep 15;2:16065. (PMID: 27629598)
Clin Pharmacol Ther. 2021 Feb;109(2):343-351. (PMID: 32602555)
N Engl J Med. 2017 Jul 6;377(1):62-70. (PMID: 28679092)
JRSM Open. 2017 Feb 01;8(3):2054270416681434. (PMID: 28321318)
Clin Trials. 2016 Jun;13(3):358-66. (PMID: 26908536)
N Engl J Med. 2021 Apr 22;384(16):1572-1573. (PMID: 33882210)
Stat Med. 2020 Feb 20;39(4):494-509. (PMID: 31846110)
BMC Med Res Methodol. 2020 Jun 24;20(1):165. (PMID: 32580702)
- Contributed Indexing:
Keywords: Adding arms; Non-concurrent controls; Platform trials
- الموضوع:
Date Created: 20220815 Date Completed: 20220817 Latest Revision: 20240513
- الموضوع:
20240513
- الرقم المعرف:
PMC9380382
- الرقم المعرف:
10.1186/s12874-022-01683-w
- الرقم المعرف:
35971069
No Comments.